



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: **Pratt**

Application No. **10/623,577**

Group Art Unit: **1614**

Filed: **July 22, 2003**

Examiner: **J. Anderson**

For: **Liquid Dosage Formulations of Donepezil**

Docket: 61368-223339 (BNAG-002-C4US)

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Information Disclosure Statement**

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the document listed on the attached PTO/SB/08A Form, a copy of which is attached hereto. A copy of the published PCT applications are also submitted herewith.

The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art.

This Information Disclosure Statement is being filed after the mailing date of a first office action on the merits, but before a Notice of Allowance or final Office Action on the merits. The Commissioner is authorized to charge the fee of \$180 to Deposit Account No. 22-0261. The Commissioner is authorized to charge any necessary fees or credit any overpayments to Deposit Account No. 22-0261.

Applicants respectfully request that the PTO return an initialed copy of the PTO/SB/08A Form with the next communication from the Office.

Respectfully submitted,

Edward D. Grief  
Registration No. 38,898

Date: September 28, 2007  
Venable LLP  
575 7<sup>th</sup> Street, NW  
Washington, DC 20004  
Phone: 202-344-4382

10/31/2007 TADDD1

00000007 220261

10623577

02 FC:1806

180.00 DA